NEW YORK (
CHANGE IN RATINGS
was downgraded to Sell at TheStreet Ratings.
was downgraded at JP Morgan from Overweight to Neutral. Company lacks near-term catalysts, JP Morgan said. $48 price target.
Extra Space Storage
was downgraded at Jefferies to Hold from Buy. Valuation hard to ignore, Jefferies said.
was upgraded at UBS to Buy from Neutral. $20 price target. Estimates were also increased on multiple near-term catalysts, UBS said.
( HGSI) was downgraded at Leerink Swann to Market Perform. See little upside potential to Glaxo's hostile bid, Leerink Swann said.
was downgraded at Jefferies to Hold from Buy. $36 price target. Valuation now reflects fundamentals, Jefferies said.
was upgraded at Keybanc from Hold to Buy. $27 price target. Management change should improve shareholder value, Keybanc said.
was downgraded at RBC Capital to Sector Perform. Valuation call, based on a $99 price target, RBC Capital said.
was downgraded at Bernstein from Outperform to Market Perform. $101 price target. Company is trying to balance between growth and margins, Bernstein said.
was downgraded at Wells Fargo from Outperform to Market Perform. Company lacks near-term catalysts, Wells Fargo said.
was downgraded at ThinkEquity from Buy to Hold. $28 price target. New analyst believes that the company lacks near-term catalysts, ThinkEquity said.
was downgraded to Hold at TheStreet Ratings.
was upgraded at Credit Suisse from Equal-Weight to Overweight. Valuation call, based on a $66 price target, Credit Suisse said.
was downgraded at Needham from Strong Buy to Hold. Company is posting lower sales and withdrew its guidance, Needham said.
was upgraded at Goldman Sachs from Neutral to Buy. Valuation call, based on a $38 price target, Goldman Sachs said.
STOCK COMMENTS / EPS CHANGES
price target was raised at Jefferies to $48. Operational improvements place company in a better position, Jefferies said.
estimates, price target were reduced at FBR Capital Markets. Shares are now seen reaching $20. Estimates were also cut, given the company's new guidance, FBR said. Market Perform rating.
Cisco Systems numbers were lowered at Oppenheimer. Shares are now seen reaching $22. Estimates were also lowered on guidance below consensus, Oppenheimer said. Outperform rating.
estimates, price target were raised at Credit Suisse. Shares are now seen reaching $50. Estimates were also increased, as Simpana is driving growth, Credit Suisse said. Neutral rating.
numbers were raised at Credit Suisse. Shares are now seen reaching $16. Estimates were also increased, given better business momentum, Credit Suisse said. Neutral rating.
price target was boosted at Bank of America/Merrill Lynch to $50. Activist investor could help unlock shareholder value, BofA/Merrill said.
estimates were increased at Benchmark through 2013. Bookings growth remains strong, Benchmark said. Buy rating and $840 price target.
numbers were lowered at Credit Suisse. Estimates were cut through 2014. Company is seeing slower production growth and lower prices, Credit Suisse said. Outperform rating and new $70 price target.
numbers were increased at Credit Suisse. Estimates were boosted through 2013. Company is seeing higher sales and cutting costs, Credit Suisse said. Outperform rating and new $40 price target.
Teva Pharmaceutical estimates were cut at Morgan Stanley through 2014. Company is facing higher generic competition and has limited pipeline visibility, Morgan Stanley said. Equal-Weight rating and new $47 price target.
>To submit a news tip, email:
READERS ALSO LIKE:
and become a fan on
This article was written by a staff member of TheStreet.